Telomerase is a telomere-specific DNA polymerase consisting of protein and RNA components, which is activated in germline cells and the majority of cancers and serves to counter the consequences of telomere shortening. The protein component, hTERT, is believed to be the catalytic subunit of human telomerase and its expression at the mRNA level correlates well with telomerase activity in vitro. Current techniques for assaying telomerase activity detect only the mean activity in a sample and are unable to isolate specific cell sub-populations. This report describes the development and validation of a cellular, immunofluorescence-based flow cytometry assay that allows detection of intranuclear hTERT while maintaining identifiable cell population characteristics. The assay was shown to be both sensitive to changes in telomerase expression and was semi-quantitative. In both cell line differentiation experiments and in primary cells, a good correlation existed between hTERT expression measured by flow cytometry and telomerase activity detected by the telomeric repeat amplification protocol (TRAP). The method developed offers a quick, simple and reproducible cellular-based assay for hTERT expression. This assay will provide a useful, new tool for future investigations, facilitating the analysis of hTERT expression in mixed cell populations. Leukemia (2000) 14, 2176-2181.
Introduction
Eukaryotic chromosomes terminate with specialised structures known as telomeres. 1 These consist of tandemly repeated DNA sequences that protect the ends of chromosomes and are important in maintaining their stability. 2 Because DNA polymerases cannot completely replicate a linear DNA molecule, telomeric DNA at the end of a chromosome may be lost with each cell division. 3 Critical shortening of telomeres is associated with cellular senescence. 4 Telomerase is a unique cellular reverse transcriptase involved in telomere maintenance. 5, 6 Its activity is detectable in the majority of cancers 7 as well as germline tissues 8 and proliferating somatic cells. 9 In cancer, telomerase activation is proposed as one mechanism by which cells can bypass senescence. Structurally, telomerase consists of protein and RNA components. One protein component, hTERT, is the catalytic subunit of human telomerase and its expression at the mRNA level correlates well with telomerase activity. 10 detection of telomerase activity and hTERT expression are primarily molecular-based techniques. These are well established and sensitive methods for the measurement of mean telomerase activity in a whole population of cells. Such methods cannot, however, measure telomerase activity in cell sub-populations. A telomerase/hTERT negative sub-population of cells will therefore not be identified within a large population of positive cells. Conversely, because the TRAP assay is highly sensitive, the activity in a small highly positive population mixed with a telomerase negative population may be interpreted as the entire population exhibiting a medium to low degree of expression. A further disadvantage of existing methods is that cell lysis is necessary for assay of telomerase or hTERT mRNA, and therefore, it is no longer possible to carry out any further or concurrent analysis on the same set of cells.
In human leukaemias, telomerase upregulation has been shown to occur during disease progression. 11, 12 It has still to be clarified whether telomerase activity in the development of cancer follows a pattern of 'reactivation' where telomerase is reactivated in previously telomerase negative cells as a result of critical telomere shortening; or if it follows a pattern of 'expansion and retention' where cells with active telomerase are there from the outset and undergo positive selection during the progression of the disease. 13, 14 However, because current methods cannot isolate cell populations it has not been possible to investigate this satisfactorily. To facilitate such investigations, a method that can measure hTERT in subpopulations is necessary.
We have developed such a method for the detection of intranuclear hTERT. We have validated the measurements in both human HL60 cells undergoing dynamic changes in telomerase during differentiation with dimethyl sulfoxide (DMSO), as well as in primary human haemopoietic cells.
Materials and methods

HL60 cell culture and induced differentiation
HL60 cells, derived from a human promyelocytic leukaemia cell line, were cultured in T75 culture flasks (Falcon, Becton Dickinson, Franklin Lakes, NJ, USA) in 25 ml of L-glutaminefree RPMI-1640 medium (GIBCO Life Technologies, Paisley, UK) containing 10% fetal calf serum and 2% L-glutamine and streptomycin and benzylpenicillin. Flasks were incubated in a 37°C environment with 5% CO 2 .
HL60 cells were induced to differentiate with DMSO (1.25% v/v) using standard methods. 15 This allowed validation of the sensitivity of the assay because it has been shown by previous authors that telomerase activity declines with induced differentiation. 16, 17 DMSO differentiation of HL60 cells was undertaken for 6 days and was confirmed by morphological analysis of cytospin preparations. After this period, 'differentiated' cells were defined as those which were approaching the metamyelocyte stage: cells that had lost their nucleolus, showed a decreased nuclear:cytoplasmic ratio of approximately 1:1 with evidence of nuclear lobulation, less basophilia and fewer cytoplasmic granules compared to the promyelocytes.
Mononuclear and neutrophil cell separation
All fresh samples were collected in vacutainers containing EDTA. The blood was diluted 1:1 with phosphate-buffered saline (PBS) and the mononuclear cells (MNC) and neutrophils were isolated from all samples by density gradient centrifugation on Ficoll-Hypaque (Lymphoprep, 1.077 g/ml, Nycomed Pharma, Oslo, Norway). Briefly, the mononuclear cells were collected and washed with PBS containing 1% fetal calf serum. The red blood cells within the sample of neutrophils were removed by the addition of red cell lysis solution (Ortho Diagnostic Systems, Raritan, NJ, USA) for 15 min. The cells were then centrifuged at 400 g for 5 min and re-suspended in PBS (80% purity).
T cell separation
To isolate T cells, magnetic activated cell sorting was carried out by with the use of a midi-MACS isolation kit and CD3 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's guidelines. Enriched samples of CD3 + T cells were obtained with 80-85% purity.
TRAP assay
For telomerase activity, cells were stored in CHAPS lysis buffer (1 × 10 5 cells in 200 l) at −70°C for analysis by the TRAP assay. The lysis buffer contained 0.5% CHAPS (3- 10 mmol/l Tris-HCl (pH 7.5), 1 mmol/l MgCl 2 , 1 mmol/l EGTA, 0.1 mmol/l Benzamidine, 5 mmol/l ␤-mercaptoethanol, and 1 ng/ml leupeptine.
The TRAP assay was performed as described previously by Kim et al 7 with the use of the TRAPeze kit (Oncor, Gaithersburg, MD, USA). Briefly this was done as follows: 2 l of test extract was added to a 48 l reaction mixture containing 5 l of 10× TRAP buffer (200 mmol/l Tris-HCl (pH 8.3), 15 mmol/l MgCl 2 , 630 mmol/l KCl, 0.5% Tween 20, 10 mmol/l EGTA); 1 l of 50× dNTP mix (2.5 mmol/l each of dATP, dTTp, dGTP and dCTP); 2 l of 32 P-labelled TS primer, 1 l of TRAP primer mix, 0.4 l of Taq polymerase and 38.6 l of PCR grade water at 30°C for 30 min. The products were amplified by 30 cycles at 94°C for 30 s and 48°C for 30 s each and were separated by electrophoresis on a 12.5% polyacrylamide gel. A manufacturer-supplied positive control, negative control (lysis buffer) and quantification template (TSR8) were also run on each gel. The gel was dried for 1 h at 80°C and then exposed on a Molecular Dynamics Storm 860 Phosphorimager (Molecular Dynamics, Sunnyville, CA, USA) and quantified using Image QuaNT software according to the manufacturer's instructions provided with the TRAPeze kit.
Immunofluorescent staining for CD 11b
Staining of the CD11b cell differentiation marker was carried out according to the manufacturer's guide lines as follows: cultured cells were suspended in cold wash buffer (PBS supplemented with 1% FCS and 1% human AB serum to block non-specific F c -mediated binding) at a concentration of 2 × 10 7 /ml. Fifty microliter aliquots of cell suspension (1 × 10 6 cells) were then placed in 5 ml flow cytometry tubes and to this 50 l of diluted antibody was added (either 30455X phycoerythrin-conjugated mouse anti-human CD11b antibody or 33815X Mouse IgG 1, isotype control (both from BD PharMingen, San Diego, CA, USA)). Antibody was left to incubate for 30 min and the cells were then re-suspended and centrifuged at 400 g in 1 ml of wash buffer twice. The final suspension was then re-suspended in 200 l of wash buffer for flow cytometry analysis. 
Results
Optimal staining method
Optimal staining was achieved by the following protocol: 5 × 10 6 HL60 cells were taken from a flask, centrifuged at 200 g for 10 min, and re-suspended for washing in 10 ml of wash buffer (PBS supplemented with 1% fetal calf serum). The cells were again centrifuged at 200 g for 10 min. The cells were then fixed in 1 ml of 2% paraformaldehyde and incubated on ice for 30 min. The cells were then washed again in 10 ml of wash buffer and re-suspended in 3ml of 0.5% Triton-X100. After permeabilisation, cells were washed once more in 10 ml of wash buffer and re-suspended in wash buffer at a concentration of 2 × 10 7 per ml. Aliquots of the cell suspension (50 l) were put into 5 ml flow cytometry tubes and to these 50 l of diluted antibody was added (either primary SC-7214 goat anti-hTERT antibody, primary SC-6370 goat anti-TP1 antibody (TP1 is another protein component of telomerase) or SC-2028 normal IgG control antibody (all from Santa Cruz Biotechnology, Santa Cruz, CA, USA)) and left to incubate for 40 min at room temperature. A manufacturer's blocking peptide was also used as an additional control in some experiments. The suspension was then washed twice by addition of 1 ml of wash buffer and centrifuging at 800 g and finally re-suspended in 100 l of wash buffer. A secondary diluted SC-2024 donkey anti-goat IgG fluorescein isothiocyanate (FITC)-conjugated antibody (Santa Cruz Biotechnology) was added and left to incubate at room temperature for 30 min. The suspension was then washed twice again (in the same way as after the addition of primary antibody). The sample was then re-suspended in 500 l of wash buffer and taken for analysis on the flow cytometer (FACS Vantage/FACScan, Becton Dickinson, San Jose, CA, USA). Figure 1a . Mean cell fluorescence was calculated by subtracting the geometric mean fluorescence of the sample with added control antibody from the geometric mean fluorescence of the sample with hTERT antibody added (Figure 1b) .
Gating was carried out as shown in
hTERT protein expression in differentiating HL60 cells
The change in hTERT protein expression of the differentiating HL60 as detected by the developed assay is shown in Figure 2a . It can be seen that hTERT protein expression in the differentiating HL60 cells declined steeply on day 4 of culture and remained low for the final 2 days. The controls that did not have DMSO added to them showed positive expression throughout the 6 day period (Figure 2b) . As a further control, the expression of TP1, another protein component of telomerase, was also assayed using this method and did not change during the 6 day study period (data not shown).
When hTERT protein expression was very low a slight negative shift was seen. This was due to a small degree of positive activity exhibited by the control normal IgG antibody used (confirmed by the use of manufacturer's blocking peptide ( Figure 3 ).
TRAP analysis
The PCR-based TRAP assay confirms the association between the expression of hTERT protein as shown by the flow cytometry assay and differentiation. It is clear that telomerase activity reduces through the 3 day period and again is virtually lost by day 4 (Figure 4a ). The data were also quantified using a Phosphorimager according to the manufacturer's protocol and these data can be shown to correlate well with the mean cell fluorescence data from the flow cytometry assay (Figure 4b and c). Statistical analysis (Pearson's product moment correlation) comparing the quantified data from the two assays across the three experiments showed a significant correlation (1% significance level, r 2 = 0.66).
Figure 3
Comparison of control antibody with manufacturer's blocking peptide. Confirmation that the negative shift seen in situations of very low expression of hTERT is due to a small degree of positive activity exhibited by the control antibody (shaded) by use of the manufacturer's blocking antibody (faint line). Note that hTERT (dark line) is positive compared to the blocking peptide.
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Figure 4
Validation of flow cytometry method for hTERT detection by comparison with conventional TRAP assay of telomerase activity in differentiating HL60 cells. 
Analysis of hTERT expression in a mixed cell population
The assay was applied to an artificially created mixed population of undifferentiated HL60 cells and DMSO differentiated Leukemia cells (day 6). Analysis showed the presence of two populations: one population showed significant positive expression of hTERT, while the second population showed no significant expression (Figure 5a ). The nature of the two populations (undifferentiated and differentiated) was further confirmed by surface staining for the CD11b differentiation marker (Figure 5b ) on another sample of cells taken from the same mixture. Concurrent dual staining for CD11b and hTERT was not possible because the fixation and permeabilising techniques required to access the intranuclear hTERT antigen interfered with the CD11b antibody's action.
Relative expression of hTERT in various haematological cell types
The assay was applied to primary blood cells obtained from 10 healthy individuals and six patients with B-CLL. Using the geometric mean cell fluorescence, it was possible to see the relative expression of the protein in the different cell types, as shown in Figure 6 . A clear difference in levels of expression can be seen between the malignant and normal cells. Mononuclear cells (MNC) derived from patients with advanced B-
Figure 5
Application of the flow cytometry assay to a mixed cell population shows that the difference in hTERT expression between differentiated and undifferentiated HL60 cells in an artificial mix can be clearly identified by the assay (a). 
Discussion
We describe an immunofluorescence flow cytometry-based assay for measurement and quantification of the hTERT component of telomerase. This method will allow sub-populations of cells to be separated according to hTERT expression prior to further manipulation, which is not possible using current techniques of telomerase detection.
The sensitivity of the assay and its ability to detect changes in hTERT expression was established using HL60 cells that had been induced to differentiate with DMSO. Differentiation with DMSO has previously been shown to result in decreased hTERT mRNA expression using RT PCR. 18, 19 No data on relative protein expression have been published previously. It can be clearly seen that the level of hTERT protein expression decreases after the first 3 days of differentiation, very sharply on day 4 and little further on days 5 and 6 (Figure 2a ). This observation correlates well with the TRAP assay which also shows an almost complete loss of telomerase activity on day 4 ( Figure 4a ). The correlation between the TRAP assay and hTERT protein expression would suggest that the hTERT antibody used is detecting functional isoforms of hTERT.
The TP1 component of telomerase, however, showed no significant change in expression during differentiation, adding further weight to the proposition that hTERT protein is the catalytic rate-limiting sub-unit of telomerase 10, 18 and that its expression at both the mRNA and protein level can be used as a diagnostic indicator of telomerase activity. Further validation of sensitivity was obtained by carrying out an analysis of a mixed cell population of differentiated and undifferentiated cells where it could be seen that the assay was able to visualise and clearly identify the difference in hTERT expression between the two populations. Surface staining of the CD11b differentiation marker gave further confirmation of the differentiation status of the two populations.
The analysis of hTERT protein expression by flow cytometry showed the general applicability of the assay and also enabled a relative quantification of telomerase activity in different components of blood. The lack of hTERT expression in neutrophils correlates well with previous findings which have generally shown that telomerase activity is not present in neutrophils. 20, 21 The low expression of hTERT protein in normal mononuclear cells and T cells is also consistent with previous findings of telomerase activity in normal blood leukocytes and may explain the continuous age-related telomere shortening in T cells despite telomerase expression. 21 The importance of developing such a sensitive assay is further underlined by the fact that hTERT mRNA expression is not readily detected by Northern blotting. 18 The analysis of mononuclear cells (MNC) derived from patients suffering from early and advanced stage B cell chronic lymphocytic leukaemia (B-CLL) shows an increase in hTERT activity according to the stage of the disease. This finding is in agreement with previous studies of CLL, which have suggested that, in NZB mice, telomerase activity correlates with disease stage 22 and in humans it is associated with both disease progression and probability of survival. 12 To conclude, we have developed a quick, safe and sensitive assay for hTERT protein expression. hTERT expression as measured by this assay correlates well with telomerase activity and the assay allows a degree of relative quantification. The antibodies used in this study were polyclonal, but as monoclonal antibodies to hTERT become commercially available, it should be possible to increase the sensitivity and reliability of the assay even further. It is hoped that the multi-parameter nature of flow cytometry and its ability to identify cellular subpopulations will enable a fuller understanding of the mechanisms of activation of telomerase and hTERT during disease progression and allow concurrent analysis of other cellular proteins which may be involved in its regulation.
